Daratumumab in AL amyloidosis
Ashutosh D Wechalekar1,2, Vaishali Sanchorawala3
1National Amyloidosis Center, University College London (Royal Free Campus), London, United Kingdom.
Blood
|May 4, 2022
Summary
Light-chain amyloidosis treatment has advanced significantly since 2021. Daratumumab-based therapies offer a new backbone, achieving deep responses, though challenges remain in early detection and amyloid removal.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Background:
- Light-chain amyloidosis (AL amyloidosis) treatment has seen recent breakthroughs.
- The first regulatory approval for an AL amyloidosis treatment occurred in 2021.
Approach:
- Reviewing the progress of AL amyloidosis treatment.
- Analyzing the impact of daratumumab-based regimens.
- Discussing future therapeutic strategies and challenges.
Key Points:
- Daratumumab-based regimens demonstrate efficacy, achieving deep hematologic and organ responses.
- These regimens represent a new therapeutic backbone for AL amyloidosis.
- Challenges persist, including early identification, accurate fibril typing, and managing advanced disease.
Conclusions:
- Significant progress has been made in AL amyloidosis treatment.
- Daratumumab offers a promising therapeutic option.
- Further research is needed for amyloid deposit removal and addressing challenges in advanced patients.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
272
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
272
03:03Amyloid Fibrils
5.7K
5.7K
01:24Parkinson's Disease: Treatment
408
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
408